|
CXR Biosciences Validates
the Impact of IPA 5.0 in Mechanism-Based Safety
Assessment
Redwood City, CA – Mar. 27,
2007 – Ingenuity Systems, the
leading provider of information solutions
for the exploration, interpretation, and analysis
of experimental data for life sciences researchers,
today launched IPA-Tox™, a pathways-driven
molecular toxicology solution that enables
researchers to understand safety issues associated
with new drug candidates. Fully integrated
within IPA 5.0, IPA-Tox provides user-friendly
software tools that rapidly assess the toxicity
and safety of compounds and includes new chemical
content containing thousands of additional
drugs and clinical candidates.
Ingenuity Pathways Analysis 5.0 (IPA) is
a software application that enables researchers
to model, analyze, and understand the complex
biological systems at the core of life science
research. IPA is deployed in all major pharmaceutical
companies and hundreds of biotechnology companies
and academic institutions globally. It supports
analysis of all experimental platforms, and
is used at all stages of the drug discovery
and development process, from target identification
and validation to identification of biomarkers,
predictive toxicology, and pharmacogenomics.
“We use IPA 5.0 in conjunction with
targeted laser microdissection microarray
analysis for high resolution mechanistic hypothesis
generation in order to determine human toxicity
from results in test species”, said
Dr. Ken Brown, Head of Molecular Biology,
CXR Biosciences. “Overlaying results
from IPA with statistical clustering of microarray
data provides new insights into the mechanisms
of toxicological responses such as oxidative
stress response, interactions of drugs with
individual enzymes such as P450’s, and
xenobiotic metabolism. This is extremely useful
for discovering biomarkers, determining toxicity
in humans, and evaluating the utility of new
toxicological models for risk assessment.”
IPA-Tox™: A New Molecular Toxicity
Solution within IPA 5.0
IPA-Tox is designed to:
- Assess the toxicity and safety of compounds
of interest early in the development process
- Provide expert molecular toxicology data
interpretation to non-expert users
- Reveal clinical pathology endpoints associated
with a dataset
- Generate new hypotheses that may not
have been revealed using traditional toxicology
approaches
- Elucidate mechanism of toxicity and identify
potential markers of toxicity
- Easily access important findings from
the scientific literature, including information
associated with cardiovascular toxicity,
nephrotoxicity, and hepatotoxicity
“We have listened to our customers
and have incorporated their feedback regarding
specific features and content to create IPA
5.0,” commented Ramon Felciano, Chief
Technology Officer of Ingenuity Systems. “By
maintaining an open dialogue with the research
community, we are able to deliver software
that meets the needs of both biologists and
bioinformaticians. To date, IPA has been cited
in more than 300 published research papers
and is now used by every major pharmaceutical
company in the world. We see this accomplishment
as a validation of our value to researchers
in the R&D process.”
In addition to IPA-Tox, IPA 5.0 also contains
significant enhancements to capabilities in
several other areas critical for life science
research:
- The IPA-Biomarker™ solution enables
researchers to identify, understand, and
prioritize biomarker candidates across different
stages of drug discovery
- New capabilities for biological interpretation
of experimental data include the ability
to easily upload experimental data from
multiple sources, send interactive networks
and pathway diagrams to colleagues, and
create pathway diagrams for publication
and presentation
Ingenuity Pathway Analysis 5.0 will be broadly
available to users in April 2007. Trials of
Ingenuity Pathways Analysis are being offered
at http://www.ingenuity.com/trial.
For more information about Ingenuity Pathways
Analysis 5.0, please email sales@ingenuity.com.
About CXR Biosciences
CXR Biosciences is a solutions provider developing
and applying new models and approaches for
drug discovery and the assessment of risks
to humans of chemicals. CXR applies a combination
of extensive experience in pre-clinical development
and risk assessment, together with the application
of proprietary post-genomic models for the
evaluation of drug metabolism and toxicity.
CXR works with over 50 customers and collaborators,
including major pharmaceutical companies,
industrial chemical companies and small drug
discovery companies. CXR Biosciences Ltd.
is located in Dundee, Scotland.
www.cxrbiosciences.com
About Ingenuity Systems
Ingenuity Systems is helping
life science researchers explore and understand
biological systems that are foundational to
human health and disease. Ingenuity delivers
capabilities and expertise to researchers
through analysis software, genome-scale computable
network databases, and knowledge management
services and infrastructure, resulting in
increased productivity and faster drugs to
market. The company was founded in 1998 and
is headquartered in Mountain View, California.
www.ingenuity.com.
Contact:
Heidi Bullock
Director, Marketing
Ingenuity Systems
650.381.5150
Holli
Dickson
Account Supervisor
Porter Novelli Life Sciences
858.527.3495
Gordon
Kennovin
Business Development Manager
CXR Biosciences
+44 1382 432 163
>
View as PDF 
|
